Orso Maria Lucherini

Orso Maria Lucherini

Auto-generated profile, based on publicly available information

Orso Maria Lucherini

Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2013 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LCLuca Cantarini
Luca Cantarini
AVAntonio Vitale
Antonio Vitale
PSPerla Scalini
Perla Scalini
CDCharles A. Dinarello
Charles A. Dinarello
Donato RiganteDonato Rigante
Donato Rigante
RCRolando Cimaz
Rolando Cimaz

5 February 2012 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
LCLuca Cantarini
Luca Cantarini
OLOrso Maria Lucherini
Orso Maria Lucherini
ABAntonio Brucato
Antonio Brucato
LBLuca Barone
Luca Barone
DCDavide Cumetti
Davide Cumetti
MIMassimo Imazio
Massimo Imazio

1 January 2014 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
FFFrancesca Finetti
Francesca Finetti
Laura PatrussiLaura Patrussi
Laura Patrussi
GMGiulia Masi
Giulia Masi
AOAnna Onnis
Anna Onnis
DGDonatella Galgano
Donatella Galgano
CBCosima T. Baldari
Cosima T. Baldari
T cell activation requires sustained signaling at the immune synapse, a specialized interface with the antigen-presenting cell (APC) that assembles following T cell antigen receptor (TCR) engagement by major histocompatibility complex (MHC)-bound peptide. Central to sustained signaling is the continuous recruitment of TCRs to the immune synapse. These TCRs are partly mobilized from an endosomal pool by polarized recycling. We have identified IFT20, a component of the intraflagellar transport (IFT) system that controls ciliogenesis, as a central regulator of TCR recycling to the immune synapse. Here, we have investigated the interplay of IFT20 with the Rab GTPase network that controls recycling. We found that IFT20 forms a complex with Rab5 and the TCR on early endosomes. IFT20 knockdown (IFT20KD) resulted in a block in the recycling pathway, leading to a build-up of recycling TCRs in Rab5+ endosomes. Recycling of the transferrin receptor (TfR), but not of CXCR4, was disrupted by IFT20 deficiency. The IFT components IFT52 and IFT57 were found to act together with IFT20 to regulate TCR and TfR recycling. The results provide novel insights into the mechanisms that control TCR recycling and immune synapse assembly, and underscore the trafficking-related function of the IFT system beyond ciliogenesis.

1 November 2012 in Autoimmunity Reviews
Verified
Journal Article
Closed access
LCLuca Cantarini
Luca Cantarini
OLOrso Maria Lucherini
Orso Maria Lucherini
IMIsabella Muscari
Isabella Muscari
BFBruno Frediani
Bruno Frediani
MGMauro Galeazzi
Mauro Galeazzi
RCRolando Cimaz
Rolando Cimaz

1 December 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
FCFrancesco Caso
Francesco Caso
LCLuisa Costa
Luisa Costa
Donato RiganteDonato Rigante
Donato Rigante
AVAntonio Vitale
Antonio Vitale
RCRolando Cimaz
Rolando Cimaz
LCLuca Cantarini
Luca Cantarini

12 March 2014 in Dermatology
Verified
Journal Article
Closed access
PDF file
AVAntonio Vitale
Antonio Vitale
Donato RiganteDonato Rigante
Donato Rigante
FCFrancesco Caso
Francesco Caso
MBMaria Giuseppina Brizi
Maria Giuseppina Brizi
MGMauro Galeazzi
Mauro Galeazzi
LCLuca Cantarini
Luca Cantarini
Recommendations related to ocular, mucosal and cutaneous involvement of Behçet's disease (BD) are mainly evidence-based, but in cases of vascular, neurological and gastrointestinal involvement there are no guidelines to define the best treatment strategy. We report three adult patients with BD, who received an interleukin-1β inhibitor by subcutaneous injections, canakinumab (at the dosage of 150 mg every 6 weeks), after failure shown by corticosteroids and different combinations of immunosuppressant agents. The prompt and sustained clinical efficacy demonstrated by canakinumab as a monotherapy supports the opportunity of using this specific anti-interleukin-1β agent as a valid therapeutic option for resistant or refractory BD. Open trials and observational studies should be performed to test canakinumab efficacy on a larger number of patients. The most appropriate dosage and intervals between administrations should be decided according to the individual patient, severity or recurrence of clinical manifestations and major organ involvement.